Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146807 | 0.91 | TLR7 (0.75) | TLR7NUDT1 | |
| SCHEMBL3134131 | 0.87 | TLR7 (0.76) | TLR7NUDT1 | |
| SCHEMBL3139086 | 0.87 | TLR7 (1.00) | TLR7NUDT1 | |
| SCHEMBL3141800 | 0.85 | TLR7 (0.80) | TLR7NUDT1 | |
| SCHEMBL3141570 | 0.85 | TLR7 (0.67) | TLR7NUDT1 | |
| SCHEMBL2912228 | 0.85 | TLR7 (0.70) | TLR7NUDT1 | |
| SCHEMBL18207658 | 0.83 | TLR7 (0.74) | TLR7NUDT1 | |
| SCHEMBL2913478 | 0.83 | TLR7 (0.74) | TLR7NUDT1 | |
| SCHEMBL3139102 | 0.82 | TLR7 (0.63) | TLR7NUDT1 | |
| SCHEMBL3138364 | 0.82 | TLR7 (0.72) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | claimed |
| CN-101203519-A | 2-amido-6-amino-8-oxopurine derivatives as Toll-like receptor modulators for the treatment of cancer and viral infections such as hepatitis c | PFIZER LTD (GB) | 2008-06-18 | — | — | CN | claimed |
| EP-1888587-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | Pfizer Limited (GB) | 2008-02-20 | — | — | EP | claimed |
| US-20060264448-A1 | Purine derivatives | PFIZER LIMITED | 2006-11-23 | — | — | US | claimed |
| WO-2006117670-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | PFIZER LIMITED (GB) | 2006-11-09 | — | — | WO | claimed |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-11-28 | — | — | US | disclosed |
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2776439-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| WO-2013068438-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2013-05-16 | — | — | WO | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-20060264448-A1 | Purine derivatives | PFIZER LIMITED | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | PNP, ADA, HPRT1 | TLR7 295/4885NUDT1 4/4885 |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | PNP, HPRT1, TYMP | TLR7 217/4885NUDT1 5/4885 |
| US-20060264448-A1 | Purine derivatives | TLR9, TLR7, TLR1 | TLR7 2/4885NUDT1 42/4885 |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | TLR7 295/4885NUDT1 4/4885 |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | TLR7 295/4885NUDT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.